Thomas Jefferson University

Jefferson Digital Commons
Division of Internal Medicine Faculty Papers &
Presentations

Division of Internal Medicine

5-1-2013

Listeria monocytogenes Cholecystitis: A Possible New Syndrome.
Jackrapong Bruminhent
Thomas Jefferson University

Timothy K Lynch
Thomas Jefferson University

Jonathan Gefen
Lankenau Medical Center, Wynnewood, PA

Jerome Santoro
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/internalfp
Part of the Infectious Disease Commons

Let us know how access to this document benefits you
Recommended Citation
Bruminhent, Jackrapong; Lynch, Timothy K; Gefen, Jonathan; and Santoro, Jerome, "Listeria
monocytogenes Cholecystitis: A Possible New Syndrome." (2013). Division of Internal Medicine
Faculty Papers & Presentations. Paper 9.
https://jdc.jefferson.edu/internalfp/9
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Division of Internal Medicine Faculty Papers & Presentations by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Case Report.
As submitted to:
The American Journal of the Medical Sciences
And later published as:
Listeria monocytogenes Cholecystitis: A Possible
New Syndrome
Jackrapong Bruminhent, MD, Timothy K. Lynch, MD, Jonathan
Gefen, MD and Jerome Santoro, MD
Volume 345, Issue 5, May 2013, Pages 414-417
DOI: 10.1097/MAJ.0b013e3182761cda

Abstract: The U.S. Food and Drug Administration
recently added potentially fatal Listeria monocytogenes
infection to the list of opportunistic infections that can
occur in patients who receive tumor necrosis factor
inhibitor therapy. In this study, the first reported case of L
monocytogenes cholecystitis associated with etanercept
use is described. It also appears that tumor necrosis factor
inhibitor therapy likely increases the risk for Listeria
cholecystitis. Clinicians need to be aware of this
association when selecting antimicrobial therapy for these
patients.

Key Indexing Terms: Cholecystitis; Tumor necrosis
factor inhibitor;
Listeria monocytogenes is an important bacterial
pathogen among patients at the extremes of age, women
during pregnancy and individuals who are receiving
immunosuppressive therapy and/or have impaired cellmediated immunity. Central nervous system (CNS)
infection and bacteremia are life-threatening
manifestations of infection with this organism especially
in immunosuppressed persons. A self-limited febrile
gastroenteritis in immunocompetent hosts is also seen, but
biliary tract infections such as cholecystitis are rare. To
date, only 5 cases of L monocytogenes cholecystitis have
been reported in the medical literature.1–3 Two of the
cases and our case occurred in patients with rheumatoid
arthritis being treated with tumor necrosis factor inhibitor
therapy (TNFIT). We postulate that TNFIT is likely a
distinct risk factor for this entity and physicians who treat
patients with biliary tract disease need to be aware of this
association so that they may suspect the diagnosis
and select an appropriate antimicrobial agent in addition
to surgical therapy.
Case Report
A 56-year-old African American male presented to the

emergency department with right upper quadrant pain and
jaundice. He had a medical history of alcoholic cirrhosis
with minimal ascites and rheumatoid arthritis. He was
receiving etanercept at a dosage of 25 mg/kg twice
weekly for the preceding 5 years without infectious
complications. He was an active alcohol user and smoker
for years. He also reported frequent consumption of
cheeses and other dairy products. On examination, he was
icteric but afebrile. His heart rate was 105 beats per
minute and blood pressure 136/70 mm Hg. An
examination of the abdomen revealed evidence of ascites
and tenderness in the right upper quadrant. Murphy’s sign
was absent.
Laboratory studies revealed a hemoglobin level of 11.5
g/dL, a white blood cell count of 16 3 109 cells per liter
with 85% neutrophils and a platelet count of 102 cells per
nanoliter. The aspartate aminotransferase level was 73
U/L, alanine aminotransferase level 38 U/L, alkaline
phosphatase level 127 U/L and total bilirubin level 9.2
mg/dL. An abdominal ultrasound revealed a distended
and thickened gallbladder with an 8-mm gallstone.
Hepatobiliary iminodiacetic acid scan findings were
compatible with acute cholecystitis. The patient
underwent laparoscopic cholecystectomy without
complication. The pathology of the gallbladder confirmed
the diagnosis of cholecystitis. Perioperatively, he received
intravenous ampicillin/ sulbactam (3 g, every 6 hours) for

3 days and was discharged home on no antimicrobial
therapy.
Two days after discharge, he was readmitted to the
hospital because ascitic fluid was draining through his
cholecystectomy ports and the microbiology laboratory
reported that a bile culture obtained intraoperatively was
growing L monocytogenes. Blood cultures that were
negative during the first admission were repeated and
were negative once again. Signs and symptoms of CNS
infection were absent and a decision was made to refrain
from performing a lumbar puncture. The patient was
given ampicillin, 2 g every 6 hours intravenously for 5
days and then declined additional intravenous therapy. He
was then discharged on on oral therapy for 4 more weeks.
During the antibiotic treatment period, his TNFIT was
withheld. The patient was seen in follow-up 1 month after
stopping the antibiotic and had returned to his baseline
status.
Discussion
Listeria monocytogenes, a facultative anaerobic
grampositive rod, has been receiving more attention lately
because of its role in recent outbreaks of food-born
illnesses. Listeria monocytogenes infection initiates with
a gastroenteritis that often goes undiagnosed. The
organism may be controlled at the latter stage or may go

on to disseminate. In patients with impaired cellular
immunity, and especially those patients receiving TNFIT,
Listeria infections have been reported with increasing
frequency and have been shown in many individuals
to cause significant morbidity and mortality.4 Allerberger
et al2 found that 2 of 467 L monocytogenes isolates were
obtained from the gallbladder. Table 1 lists the clinical
characteristics of our case and another 5 cases of L
monocytogenes cholecystitis reported in the literature.
Three patients had rheumatoid arthritis as an underlying
condition requiring TNFIT and 2 of those received
infliximab. All patients underwent a cholecystectomy
combined with antibiotic treatment. Four of the 6 patients
received ampicillin or penicillin. Bile cultures
grew the organism in 5 of the 6 patients. Pathology
reports revealed inflammation of the gallbladder
compatible with cholecystitis in 4 patients and were not
reported in 2 others. Four of these 6 patients had
prolonged and complicated hospital courses; 1 patient
died.
Since its introduction in 1998, infliximab, the first
tumor necrosis factor (TNF) inhibitor, has been used to
treat a number of autoimmune diseases. Tolerability and
therapeutic efficacy of both infliximab and etanercept are
good, and the number of patients receiving these agents is
increasing steadily.5 It is well known that TNFIT
increases ones susceptibility

to a wide variety of opportunistic pathogens including
mycobacteria, fungi and several viruses and bacteria. The
latter pathogens require an intact T-helper cell response
for recovery.6 Among the reported bacterial pathogens,
Listeria species have been recognized with increasing
frequency. The U.S. Food and Drug Administration
reported 26 cases of serious L monocytogenes infections
in the literature, including 7 deaths, among patients
treated with a TNF inhibitor.4 A systematic review and
meta-analysis also confirmed that TNFIT increased the
risk for serious infection.7 Our case and 2 previous case
reports confirmed the risk for Listeria infection associated
with TNFIT in patients with rheumatoid arthritis and, in
particular, the risk of this pathogen as a causative
organism in biliary tract disease.
Begley et al8 postulated that Listeria may be responsible
for enhanced biofilm formation in bile, which may
contribute to the survival of this pathogen in the biliary
tree. Bile tends to be resistant to bacterial growth.
Eimerman9 characterized the growth of Listeria in bile
and the murine gallbladder. Listeria apparently possesses
resistance genes that allow it to overcome bile’s inherent
bacterial toxicity. Given its tropism for the gallbladder, it
is perhaps surprising that Listeria biliary infections are not
observed more frequently. Nevertheless, the precise
pathogenesis of Listeria cholecystitis is unknown.

Although, the Gram’s stain of the gallbladder wall in
our patient did not reveal gram-positive bacilli, the
histological examination revealed inflammation of the
gallbladder compatible with cholecystitis. In addition, the
bile Gram’s stain showed gram-positive bacilli and the
cultures grew L monocytogenes suggesting its
pathological role. Previously, there have been case reports
of Listeria infection that include septic arthritis,
meningitis and sepsis associated with etanercept;
this is the first confirmed case of cholecystitis.10,11
Bacteremia and evidence of CNS infection were not
observed in our patient. It is possible that the prompt
institution of ampicillin/sulbactam may have prevented
these serious sequelae.
It is not proven that antibiotics are required for
uncomplicated cholecystitis. Nevertheless, most patients
who are hospitalized with this diagnosis do receive
antibiotic therapy. Guidelines for the empiric selection of
antimicrobial agents for biliary tract infections in a variety
of clinical settings have recently been published. Agents
such as cefazolin, ceftriaxone, cefepime, ciprofloxacin,
levofloxacin and vancomycin either alone or in
combination with metronidazole have been
recommended.12 Troxler et al13 tested 71 strains of
Listeria species and found that the organism was resistant
to the agents listed previously with the exception of
cefazolin and vancomycin. Importantly, Listeria CNS

infection has been reported to develop during therapy
with such agents as first-generation cephalosporins and
vancomycin that have in vitro activity but do not cross the
blood-brain barrier.14,15
Ampicillin and penicillin with or without
aminoglycosides are generally considered the preferred
agent for Listeria infection. The addition of an
aminoglycoside is recommended in serious infection
because the penicillins alone are not bactericidal against
this organism. An aminoglycoside was not administered
to our patient due to the lack of evidence for systemic
infection. Trimethoprim-sulfamethoxazole, a bactericidal
agent, is thought to be the best alternative for those
intolerant to penicillins.16
The U.S. Food and Drug Administration recently added
potentially fatal Listeria infection to the list of
opportunistic infections that occur in patients who receive
TNFIT.4 We believe that in suspected biliary tract
infection in a patient who is being treated with TNFIT,
strong consideration should be given to an antimicrobial
agent that is able to cross the blood-brain barrier and has
activity against Listeria.
In summary, a patient who manifests signs and/or
symptoms suggestive of infection during TNFIT must
receive a rapid and careful evaluation, with a high

suspicion for unusual pathogens and in particular L
monocytogenes. In addition, TNFIT likely increases the
risk for Listeria cholecystitis. Physicians should consider
L monocytogenes as a cause of cholecystitis in patients
who are receiving TNFIT to initiate appropriate treatment
and hopefully reduce the potentially severe morbidity and
mortality associated with this pathogen.
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